RU2015132436A - Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления - Google Patents
Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления Download PDFInfo
- Publication number
- RU2015132436A RU2015132436A RU2015132436A RU2015132436A RU2015132436A RU 2015132436 A RU2015132436 A RU 2015132436A RU 2015132436 A RU2015132436 A RU 2015132436A RU 2015132436 A RU2015132436 A RU 2015132436A RU 2015132436 A RU2015132436 A RU 2015132436A
- Authority
- RU
- Russia
- Prior art keywords
- activated antibody
- target
- activated
- seq
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 33
- 108091005804 Peptidases Proteins 0.000 title claims 7
- 239000004365 Protease Substances 0.000 title claims 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000012472 biological sample Substances 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000007017 scission Effects 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 claims 1
- 108700026078 glutathione trisulfide Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000000873 masking effect Effects 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (32)
1. Способ обнаружения наличия или отсутствия расщепляющего агента и мишени в организме субъекта или образце, который включает:
(а) контактирование субъекта или биологического образца с активируемым антителом, включающим антитело или его антигенсвязывающий фрагмент (АВ), специфически связывающийся с мишенью, маскирующую часть (ММ), ингибирующую связывание АВ активируемого антитела с мишенью в нерасщепленном состоянии, и расщепляемую часть (СМ), связанную с АВ, при этом СМ является полипептидом, функционирующим в качестве субстрата для протеазы; и
(b) измерение уровня активированного активируемого антитела в организме субъекта или биологическом образце;
при этом присутствие активированного активируемого антитела в организме субъекта или биологическом образце на детектируемом уровне указывает на наличие расщепляющего агента и мишени в организме субъекта или биологическом образце и отсутствие активированного активируемого антитела в организме субъекта или биологическом образце на детектируемом уровне указывает на отсутствие или недостаточный уровень расщепляющего агента, мишени или как расщепляющего агента, так и мишени в организме субъекта или биологическом образце.
2. Способ по п. 1, в котором активируемое антитело включает детектируемую метку.
3. Способ по п. 1, в котором уровень активируемого антитела в организме субъекта или образце измеряют при помощи вторичного реагента, специфически связывающегося с активированным антителом, при этом указанный реагент включает детектируемую метку.
4. Способ по п. 2 или 3, в котором детектируемая метка включает визуализирующий агент, контрастное вещество, фермент, флуоресцирующую метку, хромофор, краситель, радиоактивный изотоп, ионы одного или нескольких металлов или метку на основе лиганда.
5. Способ по п. 1, который является способом in vivo.
6. Способ по п. 1, который является способом in situ.
7. Способ по п. 1, который является способом ex vivo.
8. Способ по п. 1, который является способом in vitro.
9. Способ по п. 1, в котором активируемое антитело в нерасщепленном состоянии характеризуется следующим расположением в структуре от N-конца к С-концу: ММ-СМ0АВ или АВ-СМ-ММ.
10. Способ по п. 1, в котором мишень выбирают из группы мишеней, приведенных в таблице 1.
11. Способ по п. 1, в котором АВ является или выделено из антитела, выбираемого из группы антител, приведенных в таблице 2.
12. Способ по п. 1, в котором антигенсвязывающий фрагмент антитела выбирают из группы, состоящей из Fab-фрагмента, F(ab')2-фрагмента, scFv и scAb.
13. Способ по п. 1, в котором ММ обладает равновесной константой диссоциации для связывания с АВ, которая больше равновесной константы диссоциации АВ в отношении мишени.
14. Способ по п. 1, в котором ММ не препятствует или не конкурирует с АВ активируемого антитела в расщепленном состоянии за связывание с мишенью.
15. Способ по п. 1, в котором ММ является полипептидом, состоящим не более, чем из 40 аминокислот.
16. Способ по п. 1, в котором полипептидная последовательность ММ отличается от полипептидной последовательности мишени, при этом полипептидная последовательность ММ не более, чем на 50% идентична любому природному партнеру связывания АВ.
17. Способ по п. 1, в котором аминокислотная последовательность ММ не более, чем на 25% идентична аминокислотной последовательности мишени.
18. Способ по п. 1, в котором аминокислотная последовательность ММ не более, чем на 10% идентична аминокислотной последовательности мишени.
19. Способ по п. 1, в котором СМ является субстратом для протеазы, выбираемой из группы протеаз, приведенных в таблице 3.
20. Способ по п. 1, в котором СМ является полипептидом
длиной до 15 аминокислот.
21. Способ по а.1, в котором протеаза локализована в ткани вместе с мишенью, при этом протеаза расщепляет СМ в активируемом антителе, когда активируемое антитело подвергается воздействию протеазы.
22. Способ по п. 1, в котором активируемое антитело включает линкерный пептид между ММ и СМ.
23. Способ по п. 1, в котором активируемое антитело включает линкерный пептид между СМ и АВ.
24. Способ по п. 1, в котором активируемое антитело включает первый линкерный пептид (LP1) и второй линкерный пептид (LP2), при этом активируемое антитело в нерасщепленном состоянии характеризуется следующим расположением в структуре от N-конца к С-концу: MM-LP1-CM-LP2-AB или AB-LP2-CM-LP1-MM.
25. Способ по п. 24, в котором два линкерных пептида необязательно являются идентичными друг другу.
26. Способ по п. 24, в котором по меньшей мере один из линкерных пептидов LP1 или LP2 включает аминокислотную последовательность, выбираемую из группы, состоящей из (GS)n, (GGS)n, (GSGGS)n, (SEQ ID NO:33) и (GGGS)n (SEQ ID NO:34), где n означает целое число, равное по меньшей мере единице.
27. Способ по п. 24, в котором по меньшей мере один из линкерных пептидов LP1 или LP2 включает аминокислотную последовательность, выбираемую из группы, состоящей из GGSG (SEQ ID NO:35), GGSGG (SEQ ID NO:36), GSGSG (SEQ ID NO:37), GSGGG (SEQ ID NO:38), GGGSG (SEQ ID NO:39) и GSSSG (SEQ ID NO:40).
28. Способ по п. 1, в котором активируемое антитело в нерасщепленном состоянии включает спейсер, присоединенный непосредственно к ММ, и характеризуется следующим расположением в структуре от N-конца к С-концу: спейсер-ММ-СМ-АВ.
Applications Claiming Priority (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361749212P | 2013-01-04 | 2013-01-04 | |
US201361749220P | 2013-01-04 | 2013-01-04 | |
US61/749,220 | 2013-01-04 | ||
US61/749,212 | 2013-01-04 | ||
US201361749486P | 2013-01-07 | 2013-01-07 | |
US201361749529P | 2013-01-07 | 2013-01-07 | |
US61/749,486 | 2013-01-07 | ||
US61/749,529 | 2013-01-07 | ||
US201361755810P | 2013-01-23 | 2013-01-23 | |
US61/755,810 | 2013-01-23 | ||
US201361763237P | 2013-02-11 | 2013-02-11 | |
US61/763,237 | 2013-02-11 | ||
US201361830940P | 2013-06-04 | 2013-06-04 | |
US61/830,940 | 2013-06-04 | ||
US201361897659P | 2013-10-30 | 2013-10-30 | |
US61/897,659 | 2013-10-30 | ||
PCT/US2014/010216 WO2014107599A2 (en) | 2013-01-04 | 2014-01-03 | Compositions and methods for detecting protease activity in biological systems |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2015132436A true RU2015132436A (ru) | 2017-02-09 |
Family
ID=51062553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015132436A RU2015132436A (ru) | 2013-01-04 | 2014-01-03 | Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления |
Country Status (9)
Country | Link |
---|---|
US (3) | US10261083B2 (ru) |
EP (1) | EP2941643A4 (ru) |
JP (3) | JP6605957B2 (ru) |
CN (2) | CN112162094A (ru) |
AU (2) | AU2014204015A1 (ru) |
CA (1) | CA2896282C (ru) |
HK (1) | HK1210831A1 (ru) |
RU (1) | RU2015132436A (ru) |
WO (1) | WO2014107599A2 (ru) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2754072C (en) | 2009-03-02 | 2019-01-15 | Massachusetts Institute Of Technology | Methods and products for in vivo enzyme profiling |
CA3214092A1 (en) | 2011-03-15 | 2012-09-20 | Massachusetts Institute Of Technology | Multiplexed detection with isotope-coded reporters |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
IN2014MN02635A (ru) * | 2012-06-22 | 2015-10-16 | Cytomx Therapeutics Inc | |
EP2941643A4 (en) | 2013-01-04 | 2016-09-28 | Cytomx Therapeutics Inc | Compositions and methods for detecting proteinase activity in biological systems |
US9517276B2 (en) * | 2013-06-04 | 2016-12-13 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
CN105452481A (zh) | 2013-06-07 | 2016-03-30 | 麻省理工学院 | 基于亲和力检测配体编码的合成性生物标记物 |
CA2918795A1 (en) * | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
AU2014324884B2 (en) * | 2013-09-25 | 2020-03-26 | Cytomx Therapeutics, Inc | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
WO2015066279A2 (en) * | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
WO2015089283A1 (en) | 2013-12-11 | 2015-06-18 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
DK3628328T3 (da) | 2014-01-31 | 2022-12-05 | Cytomx Therapeutics Inc | Matriptase- og u-plasminogen-aktivatorsubstrater og andre spaltelige dele og fremgangsmåder til anvendelse deraf |
EP3172235A2 (en) | 2014-07-25 | 2017-05-31 | Cytomx Therapeutics Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
US20170233824A1 (en) * | 2014-08-18 | 2017-08-17 | Adrastia Biotech Corporation | Systems and methods of detecting solid tumor cancer |
EP3733696A1 (en) | 2015-01-13 | 2020-11-04 | City of Hope | Ctla4-binding protein peptide-linker masks |
MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
SG10201913767VA (en) | 2015-05-04 | 2020-03-30 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
JP6900323B2 (ja) | 2015-05-29 | 2021-07-07 | アジェナス インコーポレイテッド | 抗ctla−4抗体およびその使用方法 |
JP2018526972A (ja) | 2015-06-16 | 2018-09-20 | ジェネンテック, インコーポレイテッド | 抗cd3抗体及び使用方法 |
JP2018518972A (ja) * | 2015-06-26 | 2018-07-19 | ユニバーシティ オブ サザン カリフォルニア | 腫瘍特異的活性化のためのマスキングキメラ抗原受容体t細胞 |
CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药(上海)有限公司 | 可活化的嵌合受体 |
ES2873846T3 (es) | 2015-11-19 | 2021-11-04 | Revitope Ltd | Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas |
RU2749050C2 (ru) | 2016-01-27 | 2021-06-03 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
EP3213768A1 (en) | 2016-03-01 | 2017-09-06 | LODOCO CLINICAL Kft | Combination of low dose immune checkpoint blockade with high dose il-2 for treating metastatic cancer |
US11448643B2 (en) | 2016-04-08 | 2022-09-20 | Massachusetts Institute Of Technology | Methods to specifically profile protease activity at lymph nodes |
EP3452407B1 (en) | 2016-05-05 | 2024-04-03 | Massachusetts Institute Of Technology | Methods and uses for remotely triggered protease activity measurements |
CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
KR102504605B1 (ko) | 2016-12-07 | 2023-03-02 | 아게누스 인코포레이티드 | 항-ctla-4 항체 및 이의 사용 방법 |
CN110036034A (zh) | 2016-12-09 | 2019-07-19 | 西雅图遗传学公司 | 卷曲螺旋掩蔽的二价抗体 |
US11519905B2 (en) | 2017-04-07 | 2022-12-06 | Massachusetts Institute Of Technology | Methods to spatially profile protease activity in tissue and sections |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
EA202090247A1 (ru) | 2017-07-14 | 2020-05-12 | Цитомкс Терапьютикс, Инк. | Антитела против cd166 и их применения |
EP3658165A4 (en) * | 2017-07-26 | 2021-09-01 | Oncorus, Inc. | ONCOLYTIC VIRUS VECTORS AND USES THEREOF |
SG11202002384VA (en) | 2017-10-14 | 2020-04-29 | Cytomx Therapeutics Inc | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
US11180552B2 (en) | 2017-12-01 | 2021-11-23 | Seagen Inc. | CD47 antibodies and uses thereof for treating cancer |
MA51793A (fr) | 2018-02-08 | 2020-12-16 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation |
US11054428B2 (en) | 2018-03-05 | 2021-07-06 | Massachusetts Institute Of Technology | Inhalable nanosensors with volatile reporters and uses thereof |
JP2021518603A (ja) | 2018-03-20 | 2021-08-02 | シートムエックス セラピューティクス,インコーポレイテッド | 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法 |
JP7460609B2 (ja) | 2018-05-14 | 2024-04-02 | ウェアウルフ セラピューティクス, インコーポレイテッド | 活性化可能なインターロイキン-2ポリペプチド及びその使用方法 |
AU2019271149B2 (en) | 2018-05-14 | 2023-07-13 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
US11835522B2 (en) | 2019-01-17 | 2023-12-05 | Massachusetts Institute Of Technology | Sensors for detecting and imaging of cancer metastasis |
MX2021013766A (es) | 2019-05-14 | 2022-02-21 | Werewolf Therapeutics Inc | Restos de separacion y metodos de uso de los mismos. |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
US20220226514A1 (en) * | 2019-05-17 | 2022-07-21 | Cytomx Therapeutics, Inc. | Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates |
WO2020247574A1 (en) | 2019-06-05 | 2020-12-10 | Seattle Genetics, Inc. | Methods of purifying masked antibodies |
TW202112354A (zh) | 2019-06-05 | 2021-04-01 | 美商西雅圖遺傳學公司 | 遮蔽抗體調配物 |
MX2022007158A (es) | 2019-12-13 | 2022-07-11 | Genentech Inc | Anticuerpos anti-ly6g6d y metodos de uso. |
WO2021207657A1 (en) | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
CN111830254B (zh) * | 2020-07-29 | 2022-07-26 | 武汉生之源生物科技股份有限公司 | 一种基质金属蛋白酶-3测定试剂盒及其制备方法 |
CN116973566A (zh) * | 2021-02-03 | 2023-10-31 | 广东菲鹏生物有限公司 | 一种鉴别结合突变型抗原的抗体的方法及试剂 |
EP4370211A1 (en) | 2021-07-14 | 2024-05-22 | Seagen Inc. | Antibody masking domains |
CN117813378A (zh) * | 2021-07-26 | 2024-04-02 | 乔治亚技术研究公司 | 用于通过免疫细胞展示进行体内蛋白酶谱分析的组合物和方法 |
WO2023034825A1 (en) * | 2021-08-30 | 2023-03-09 | Cytomx Therapeutics, Inc. | Method for determining protease activity in a biological sample |
WO2023049825A1 (en) | 2021-09-24 | 2023-03-30 | Seagen Inc. | Improved antibody masking domains |
WO2023168239A2 (en) * | 2022-03-01 | 2023-09-07 | The Board Of Regents Of The University Of Texas System | Methods for identifying lilrb ligands and blocking antibodies |
US11958906B2 (en) | 2022-04-13 | 2024-04-16 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1286700A2 (en) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
AU2001293995B2 (en) | 2000-10-09 | 2005-10-13 | Cytomx Therapeutics, Inc. | Therapeutic antibodies |
US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
EP1919931A4 (en) | 2005-08-31 | 2010-01-20 | Univ California | CELLULAR LIBRARIES OF PEPTIDE SEQUENCES (CLIPS) AND METHODS OF USE THEREOF |
EP1993608A1 (en) | 2006-03-10 | 2008-11-26 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
EP2514767A1 (en) | 2006-12-19 | 2012-10-24 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
EP3492488A1 (en) | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
US20110178279A1 (en) * | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
JP2012511033A (ja) * | 2008-12-08 | 2012-05-17 | テゴファーム コーポレーション | 多価化合物の可逆阻害用マスキングリガンド |
CN102482347B (zh) | 2009-01-12 | 2017-04-26 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
EP2427479B1 (en) | 2009-05-07 | 2018-11-21 | The Regents of The University of California | Antibodies and methods of use thereof |
SG11201406943XA (en) | 2012-04-27 | 2014-12-30 | Cytomx Therapeutics Inc | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
IN2014MN02635A (ru) | 2012-06-22 | 2015-10-16 | Cytomx Therapeutics Inc | |
EP2941643A4 (en) | 2013-01-04 | 2016-09-28 | Cytomx Therapeutics Inc | Compositions and methods for detecting proteinase activity in biological systems |
-
2014
- 2014-01-03 EP EP14735246.2A patent/EP2941643A4/en active Pending
- 2014-01-03 WO PCT/US2014/010216 patent/WO2014107599A2/en active Application Filing
- 2014-01-03 JP JP2015551784A patent/JP6605957B2/ja active Active
- 2014-01-03 US US14/147,324 patent/US10261083B2/en active Active
- 2014-01-03 RU RU2015132436A patent/RU2015132436A/ru unknown
- 2014-01-03 CA CA2896282A patent/CA2896282C/en active Active
- 2014-01-03 AU AU2014204015A patent/AU2014204015A1/en not_active Abandoned
- 2014-01-03 CN CN202010717082.7A patent/CN112162094A/zh active Pending
- 2014-01-03 CN CN201480011969.7A patent/CN105008918A/zh active Pending
-
2015
- 2015-11-19 HK HK15111420.0A patent/HK1210831A1/xx unknown
-
2018
- 2018-10-18 AU AU2018250437A patent/AU2018250437B2/en active Active
-
2019
- 2019-02-15 US US16/277,497 patent/US11035859B2/en active Active
- 2019-10-17 JP JP2019190445A patent/JP7001652B2/ja active Active
-
2021
- 2021-04-30 US US17/246,167 patent/US11867695B2/en active Active
- 2021-12-23 JP JP2021209234A patent/JP7223832B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP2941643A2 (en) | 2015-11-11 |
US11867695B2 (en) | 2024-01-09 |
US20140255313A1 (en) | 2014-09-11 |
JP2022036134A (ja) | 2022-03-04 |
AU2014204015A1 (en) | 2015-07-09 |
CN112162094A (zh) | 2021-01-01 |
CN105008918A (zh) | 2015-10-28 |
US10261083B2 (en) | 2019-04-16 |
WO2014107599A3 (en) | 2014-09-04 |
AU2018250437B2 (en) | 2020-09-03 |
WO2014107599A2 (en) | 2014-07-10 |
US20200025761A1 (en) | 2020-01-23 |
AU2018250437A1 (en) | 2018-11-15 |
EP2941643A4 (en) | 2016-09-28 |
JP2020098195A (ja) | 2020-06-25 |
CA2896282A1 (en) | 2014-07-10 |
US11035859B2 (en) | 2021-06-15 |
CA2896282C (en) | 2021-07-20 |
JP7001652B2 (ja) | 2022-02-21 |
JP6605957B2 (ja) | 2019-11-13 |
US20210382053A1 (en) | 2021-12-09 |
JP7223832B2 (ja) | 2023-02-16 |
HK1210831A1 (en) | 2016-05-06 |
JP2016505138A (ja) | 2016-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015132436A (ru) | Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления | |
JP2016505138A5 (ru) | ||
EP3978927A2 (en) | Methods and reagents for diagnosis of sars-cov-2 infection | |
Zougman et al. | Integrated analysis of the cerebrospinal fluid peptidome and proteome | |
ES2440597T3 (es) | Ensayos de actividad de endopeptidasa re-dirigida basados en inmunología | |
Guillon-Munos et al. | Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors | |
ES2665996T3 (es) | Anticuerpo agonista de klotho-beta para utilizar en el tratamiento de diabetes mellitus o resistencia a la insulina | |
US20160223529A1 (en) | Bimolecular protease-based biosensor | |
Marimuthu et al. | Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome | |
RU2014147684A (ru) | Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения | |
Lázár et al. | Structure–function analysis of peroxidasin provides insight into the mechanism of collagen IV crosslinking | |
JP2015516813A5 (ru) | ||
RU2011108943A (ru) | Профилактика, лечение и диагностика инфекции, вызванной бактериями p.gingivalis | |
WO2016065415A1 (en) | Bimolecular autoinhibited biosensor | |
DK2904403T3 (en) | PROCEDURE FOR DIAGNOSTICATION OR MONITORING OF Kidney Function or Diagnosis of Kidney Function | |
JPWO2006098464A1 (ja) | 前立腺がんの診断方法 | |
Wang et al. | Further optimization of peptide substrate enhanced assay performance for BoNT/A detection by MALDI-TOF mass spectrometry | |
Leung et al. | Osteopontin fragments with intact thrombin-sensitive site circulate in cervical cancer patients | |
JP5252339B2 (ja) | Pad4及び抗pad4抗体の測定方法並びに関節リウマチの検出方法 | |
DK1572225T3 (en) | THROMBOSPOND INFRAGMENTS AND APPLICATIONS THEREOF IN CLINICAL CANCER ASSAYS AND CREATION OF ANTIBODIES AND OTHER BINDING AGENTS | |
AR071885A1 (es) | Proteinas de union al receptor de interleuquina 21 | |
CN111051889B (zh) | 检测癌症的方法和检测试剂 | |
CN108291915B (zh) | Ed-b蛋白在诊断组织增生中的应用 | |
RU2005115973A (ru) | Растворимые субстраты на основе notch для гамма-секретазы, а также способы и композиции для их применения | |
Crisci et al. | Immune characterization of long pentraxin 3 in pigs infected with influenza virus |